| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037390638 |
| P356 | DOI | 10.1038/SJ.BJC.6603839 |
| P932 | PMC publication ID | 2360298 |
| P698 | PubMed publication ID | 17595666 |
| P5875 | ResearchGate publication ID | 232749265 |
| P2093 | author name string | Y Qiu | |
| S J Harper | |||
| A Orlando | |||
| D O Bates | |||
| H Rigby | |||
| A H R Varey | |||
| D B A Dunn | |||
| R O Pritchard-Jones | |||
| P2860 | cites work | Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma | Q24540048 |
| Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid | Q29617640 | ||
| Splicing variant of Cdc42 interacting protein-4 disrupts beta-catenin-mediated cell-cell adhesion: expression and function in renal cell carcinoma | Q30160023 | ||
| Molecular and biological properties of vascular endothelial growth factor | Q33737216 | ||
| Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes | Q33986146 | ||
| Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene | Q33992355 | ||
| The histogenesis and biologic behavior of primary human malignant melanomas of the skin | Q34054176 | ||
| Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system | Q34086787 | ||
| Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma | Q34086791 | ||
| Molecular characterization of lymphatic endothelial cells. | Q34415420 | ||
| Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas | Q35746653 | ||
| Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival | Q35791518 | ||
| Aberrant and alternative splicing in cancer | Q35936123 | ||
| Unbalanced alternative splicing and its significance in cancer | Q36425627 | ||
| Lymphatic density and metastatic spread in human malignant melanoma | Q38449027 | ||
| Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma | Q38449704 | ||
| Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma | Q38449947 | ||
| VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression | Q40497297 | ||
| Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability | Q40503986 | ||
| VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma | Q44068637 | ||
| Interstitial flow as a guide for lymphangiogenesis | Q44353733 | ||
| Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin | Q44598505 | ||
| Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. | Q45052632 | ||
| Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels | Q46436248 | ||
| Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. | Q46727452 | ||
| Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions | Q47404143 | ||
| Effects of high intensity focused ultrasound on vascular endothelial growth factor in melanoma bearing mice | Q50250262 | ||
| Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. | Q50517186 | ||
| Developmental biology. One cell, two fates. | Q52162753 | ||
| Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. | Q52548040 | ||
| U.K. guidelines for the management of cutaneous melanoma | Q56828452 | ||
| Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis | Q57382204 | ||
| Expression of VEGF in routinely fixed material using a new monoclonal | Q58212231 | ||
| The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term | Q60061937 | ||
| Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group | Q74116594 | ||
| Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1 | Q77349758 | ||
| The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor | Q79097464 | ||
| Chemokine-mediated migration of melanoma cells towards lymphatics--a mechanism contributing to metastasis | Q79387215 | ||
| The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo | Q82309242 | ||
| VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice | Q83878552 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 223-230 | |
| P577 | publication date | 2007-06-26 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma | |
| P478 | volume | 97 |
| Q50071368 | A computational analysis of pro-angiogenic therapies for peripheral artery disease |
| Q30433214 | A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. |
| Q28297381 | Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged |
| Q36345822 | Alternative splicing and its impact as a cancer diagnostic marker |
| Q34854858 | Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance |
| Q35692268 | Alternative splicing of VEGFA, APP and NUMB genes in colorectal cancer |
| Q52564290 | Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. |
| Q92255538 | An Intricate Connection between Alternative Splicing and Phenotypic Plasticity in Development and Cancer |
| Q35380959 | Angiogenesis and melanoma - from basic science to clinical trials. |
| Q38186064 | Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies |
| Q34244804 | Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity |
| Q38051013 | Assessing the in vivo efficacy of biologic antiangiogenic therapies |
| Q36700844 | Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab |
| Q35234354 | Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma |
| Q34347768 | Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms |
| Q39730550 | Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells |
| Q42427504 | Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios |
| Q92513343 | Comparison of the ligand-binding properties of fluorescent VEGF-A isoforms to VEGF receptor 2 in living cells and membrane preparations using NanoBRET |
| Q34610427 | Current concepts of metastasis in melanoma. |
| Q34918179 | Detection of VEGF-A(xxx)b isoforms in human tissues |
| Q60061928 | Diabetes-induced microvascular complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain |
| Q34261539 | Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale |
| Q41565732 | Dynamics and implications of circulating anti-angiogenic VEGF-A165b isoform in patients with ST-elevation myocardial infarction. |
| Q39450742 | Effects of exogenous VEGF(165)b on invasion and migration of human lung adenocarcinoma A549 cells |
| Q43213739 | Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors |
| Q39613028 | Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. |
| Q37083055 | Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia |
| Q37266075 | HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. |
| Q38171229 | Hallmarks of alternative splicing in cancer |
| Q47681462 | Hypoxia-Inducible Factors and Cancer |
| Q92564057 | In silico analysis of alternative splicing on drug-target gene interactions |
| Q38072488 | Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes |
| Q52717006 | Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. |
| Q34089123 | Molecular diversity of VEGF-A as a regulator of its biological activity. |
| Q42222152 | Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression |
| Q35885946 | Ovarian VEGF(165)b expression regulates follicular development, corpus luteum function and fertility |
| Q38776406 | Pharmacology of Modulators of Alternative Splicing |
| Q36398266 | Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation |
| Q33828636 | Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy |
| Q84960775 | Propranolol as first-line treatment for rapidly proliferating Infantile Haemangiomas |
| Q33541827 | Recombinant human VEGF165b inhibits experimental choroidal neovascularization |
| Q91657011 | Regulation of Gene Expression under Hypoxic Conditions |
| Q41953953 | Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia. |
| Q38131857 | Regulation of placental angiogenesis |
| Q28513991 | Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis |
| Q86334032 | Relative expression of vascular endothelial growth factor isoforms in squamous cell carcinoma of the head and neck |
| Q35131059 | Relevance of VEGF and nephrin expression in glomerular diseases |
| Q50913259 | SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. |
| Q39569640 | Sp1 inhibition-mediated upregulation of VEGF 165 b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549. |
| Q26798158 | Splicing Regulators and Their Roles in Cancer Biology and Therapy |
| Q38018123 | Splicing in oncogenesis and tumor suppression |
| Q33994399 | Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma |
| Q58758774 | The Cancer Spliceome: Reprograming of Alternative Splicing in Cancer |
| Q36037600 | The Roles of Angiogenesis in Malignant Melanoma: Trends in Basic Science Research over the Last 100 Years |
| Q33901839 | The anti-angiogenic isoforms of VEGF in health and disease |
| Q34792239 | The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy |
| Q36608586 | The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. |
| Q42511450 | The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas |
| Q36542093 | The role of VEGF 165b in pathophysiology |
| Q52564106 | The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review). |
| Q36907325 | The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion |
| Q39678637 | The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo |
| Q33888458 | Therapeutic potential of manipulating VEGF splice isoforms in oncology |
| Q37288883 | Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis |
| Q37166978 | Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD |
| Q37095185 | VEGF 165 b in the developing vasculatures of the fetal human eye. |
| Q40001026 | VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. |
| Q37951859 | VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. |
| Q35369677 | VEGF spliced variants: possible role of anti-angiogenesis therapy |
| Q37400534 | VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo |
| Q37197773 | VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level |
| Q37035757 | VEGF-A splicing: the key to anti-angiogenic therapeutics? |
| Q37149053 | VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. |
| Q89930457 | VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment |
| Q37606226 | VEGF-VEGFR Signals in Health and Disease |
| Q91336478 | VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop |
| Q39613701 | VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A. |
| Q36137701 | Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies |
| Q27004077 | Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases |
| Q42548827 | Vascular endothelial growth factor and the collateral circulation: the story continues |
| Q33721685 | Vascular endothelial growth factor signaling in hypoxia and inflammation |
Search more.